Today: 7 February 2026
Subscribe
Browse Category

NYSE:JNJ News 31 January 2026 - 7 February 2026

Johnson & Johnson stock rises on talc-court ruling — FDA Class I recall keeps JNJ in focus

Johnson & Johnson stock rises on talc-court ruling — FDA Class I recall keeps JNJ in focus

JNJ shares rose 0.9% to $239.99 in after-hours trading. A New Jersey appeals court barred Beasley Allen from representing plaintiffs in state talc cases against J&J, citing ethical concerns. The FDA announced a Class I recall for certain CEREPAK detachable coil systems sold by J&J’s MedTech unit, linked to four injuries and one death.
7 February 2026
····
Johnson & Johnson stock ticks up on talc-case ruling as FDA recall adds new wrinkle

Johnson & Johnson stock ticks up on talc-case ruling as FDA recall adds new wrinkle

A New Jersey appeals court barred Beasley Allen from representing plaintiffs in state talc lawsuits against Johnson & Johnson, prompting the firm to plan an appeal. J&J shares edged up 0.2% to $238.34 by midday. The FDA issued its most serious recall for certain CEREPAK detachable coil systems, citing risks of severe injury or death.
6 February 2026
·····
P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

Procter & Gamble shares rose 1.1% to $158.61 in after-hours trading, outperforming broader market declines. CEO Ma. Fatima D. Francisco sold 8,000 shares at $158 each on Feb. 4, according to a regulatory filing. U.S. jobless claims increased to 231,000, while job openings fell to 6.542 million. P&G’s Gillette Venus announced a partnership with U.S. Figure Skating ahead of the Milano Cortina Winter Games.
6 February 2026
·····
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
5 February 2026
····
Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

The FDA issued an early alert on Abiomed Impella RP heart pumps, citing a pressure sensor defect linked to 22 serious injuries but no deaths. Johnson & Johnson shares rose 0.6% to $234.47, holding steady after hours. Traders await further FDA updates and MedTech data at the AF Symposium on Feb. 6. The S&P 500 fell 0.51% while the Dow gained 0.53%.
5 February 2026
·····
Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson shares rose 1% to $235.50 Wednesday, bucking a broader market decline. RBC raised its price target to $255, citing strong financials despite ongoing talc litigation. New data showed ERLEADA cut prostate cancer death risk by 51% versus darolutamide. Investors await updates at the AF Symposium on Feb. 6 and a TD Cowen event on March 3.
4 February 2026
·····
Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson stock price rises after RBC target hike as investors eye talc risk, new data

Johnson & Johnson shares rose about 1% Tuesday to $233.10 after RBC Capital Markets raised its price target, citing ongoing talc litigation risk. The company highlighted new real-world data showing ERLEADA cut death risk by 51% in certain prostate cancer patients. Investors await management’s next comments at the TD Cowen conference on March 3.
4 February 2026
····
Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Johnson & Johnson shares rose about 1.4% to $233.87 Tuesday after unveiling new pulsed-field ablation and imaging technologies ahead of the AF Symposium. The company will present Omny-AF pilot data on Feb. 6 and its stock will trade ex-dividend on Feb. 24. Medtronic announced a $585 million CathWorks acquisition as PFA competition intensifies.
3 February 2026
·····
Johnson & Johnson stock rises as new Erleada survival data lands

Johnson & Johnson stock rises as new Erleada survival data lands

Johnson & Johnson shares rose 0.8% to $229.09 midday after the company reported real-world data showing Erleada cut the risk of death by 51% over 24 months versus darolutamide in advanced prostate cancer. The move tracked broader U.S. market gains. Investors await further feedback from doctors and insurers, and key dates including a Feb. 24 ex-dividend.
2 February 2026
·····
Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson stock price: JNJ in focus after EU panel backs Akeega expansion

Johnson & Johnson shares closed Friday nearly flat at $227.25 after EU advisers backed expanded use of its prostate cancer drug Akeega. The Committee for Medicinal Products for Human Use recommended approval for patients with BRCA1/2 mutations. The final decision rests with the European Commission. Traders are watching Monday’s open and upcoming U.S. economic data.
1 February 2026
·····
Johnson & Johnson stock: Talc-court twist and EU drug nod set up next week

Johnson & Johnson stock: Talc-court twist and EU drug nod set up next week

Johnson & Johnson shares slipped 3 cents to $227.25 Friday after a U.S. judge dismissed a fraud lawsuit over its talc bankruptcy strategy. The European Medicines Agency’s drug panel recommended expanding J&J’s AKEEGA use for certain prostate cancer patients. Investors await Monday’s trading for signs of shifts in sentiment on litigation and drug approvals.
31 January 2026
····
1 2 3 … 11

Stock Market Today

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Go toTop